BRPI0509936A - peptìdios terapêuticos - Google Patents

peptìdios terapêuticos

Info

Publication number
BRPI0509936A
BRPI0509936A BRPI0509936-6A BRPI0509936A BRPI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A BR PI0509936 A BRPI0509936 A BR PI0509936A
Authority
BR
Brazil
Prior art keywords
therapeutic peptides
ligand
product
sulfonation
hydroxylation
Prior art date
Application number
BRPI0509936-6A
Other languages
English (en)
Inventor
Mumtaz Virji
Original Assignee
Univ Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0408390A external-priority patent/GB0408390D0/en
Priority claimed from GB0419594A external-priority patent/GB0419594D0/en
Application filed by Univ Bristol filed Critical Univ Bristol
Publication of BRPI0509936A publication Critical patent/BRPI0509936A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C07K14/212—Moraxellaceae, e.g. Acinetobacter, Moraxella, Oligella, Psychrobacter
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEPTìDIOS TERAPêUTICOS. A presente invenção refere-se a um ligante isolado de proteína de membrana externa de Moraxella catarrhalis, que se liga a receptores de CEACAM, o dito ligante compreendendo um domínio de ligação de receptor compreendendo uma seqüência de aminoácidos selecionada do grupo descrito, ou um fragmento, homólogo, equivalente funcional, derivado, degenerado ou produto de hidroxilação, sulfonação ou glicosilação ou outro produto de processamento secundário da mesma. A invenção também proporciona medicamentos e vacinas compreendendo o dito ligante, e o seu uso no tratamento ou profilaxia da infecção. Também se proporciona um método de triagem para a identificação de novos compostos terapêuticos.
BRPI0509936-6A 2004-04-15 2005-04-15 peptìdios terapêuticos BRPI0509936A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0408390A GB0408390D0 (en) 2004-04-15 2004-04-15 Therapeutic peptides
GB0419594A GB0419594D0 (en) 2004-09-03 2004-09-03 Therapeutic peptides
PCT/GB2005/001465 WO2005099337A2 (en) 2004-04-15 2005-04-15 Therapeutic peptides

Publications (1)

Publication Number Publication Date
BRPI0509936A true BRPI0509936A (pt) 2007-09-25

Family

ID=35033424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509936-6A BRPI0509936A (pt) 2004-04-15 2005-04-15 peptìdios terapêuticos

Country Status (11)

Country Link
EP (2) EP1735446A2 (pt)
JP (2) JP4960219B2 (pt)
KR (1) KR20070001274A (pt)
AU (1) AU2005232437B2 (pt)
BR (1) BRPI0509936A (pt)
CA (1) CA2563332A1 (pt)
IL (1) IL178517A0 (pt)
MX (1) MXPA06011501A (pt)
NO (1) NO20065201L (pt)
NZ (1) NZ551204A (pt)
WO (1) WO2005099337A2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008029271A2 (en) 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
EP2042187A1 (en) * 2007-09-27 2009-04-01 Charité-Universitätsmedizin Berlin (Charité) Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis
EP3087099A4 (en) * 2013-12-23 2017-07-19 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
GB201803692D0 (en) * 2018-03-08 2018-04-25 Glaxosmithkline Biologicals Sa Immunogenic composition
US20230407291A1 (en) * 2020-11-17 2023-12-21 Yale University Targeting host-bacteria interactions for the treatment of microbiota-mediated diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948625B1 (en) * 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
GB0222764D0 (en) * 2002-10-02 2002-11-06 Univ Bristol Therapeutic peptide

Also Published As

Publication number Publication date
EP2468863A1 (en) 2012-06-27
EP1735446A2 (en) 2006-12-27
WO2005099337A2 (en) 2005-10-27
JP4960219B2 (ja) 2012-06-27
WO2005099337A3 (en) 2006-08-10
CA2563332A1 (en) 2005-10-27
IL178517A0 (en) 2007-02-11
MXPA06011501A (es) 2007-01-26
AU2005232437B2 (en) 2011-10-06
KR20070001274A (ko) 2007-01-03
JP2012097099A (ja) 2012-05-24
NO20065201L (no) 2006-11-13
JP2007532618A (ja) 2007-11-15
AU2005232437A1 (en) 2005-10-27
NZ551204A (en) 2010-03-26

Similar Documents

Publication Publication Date Title
Ratanabanangkoon et al. A simple and novel strategy for the production of a pan-specific antiserum against elapid snakes of Asia
BR112019021991A2 (pt) Proteínas de ligação ao antígeno trem2 e seus usos
EA202192910A1 (ru) Соединения, направленные на белки, и содержащие их фармацевтические композиции, и их терапевтическое применение
UA103154C2 (uk) Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
BRPI0716811B8 (pt) anticorpos antirreceptor alfa de folato humano,usos e método de produção dos mesmos, coquetel dos mesmos, vetor de expressão, microrganismo hospedeiro, composição e combinação farmacêuticas, e método para o diagnóstico ou reprodução de imagens de carcinoma ovariano ou suas metástases
El-Bitar et al. Smp76, a scorpine-like peptide isolated from the venom of the scorpion Scorpio maurus palmatus, with a potent antiviral activity against hepatitis C virus and dengue virus
Zhang et al. Tongue sole (Cynoglossus semilaevis) prothymosin alpha: cytokine-like activities associated with the intact protein and the C-terminal region that lead to antiviral immunity via Myd88-dependent and-independent pathways respectively
NO20083793L (no) Antistoffer mot amyloid-beta peptid
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
JP2003521477A (ja) プリオン蛋白質ペプチドおよびその使用
BR112023025194A2 (pt) Anticorpos anti-sirp-alfa
BRPI0413495A (pt) reagentes de peptìdeos especìficos para prìons e seus usos
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor
AR122213A1 (es) Anticuerpos anti-cd200r1 y métodos de uso de estos
BRPI0509936A (pt) peptìdios terapêuticos
AR117327A1 (es) Anticuerpos anti-cd96 y métodos de uso de estos
Jerman et al. OFD1 and flotillins are integral components of a ciliary signaling protein complex organized by polycystins in renal epithelia and odontoblasts
BR0315031A (pt) Peptìdios terapêuticos
BR112021009912A2 (pt) Proteína de ligação a alfa receptor de folato, composição, e, método para produção da proteína de ligação a folr1
Huai et al. Interaction of transient receptor potential vanilloid 4 with annexin A2 and tubulin beta 5
Amini et al. Overexpression of protein kinase Mζ in the hippocampus mitigates Alzheimer’s disease-related cognitive deficit in rats
Ronzitti et al. Yessotoxin induces the accumulation of altered E-cadherin dimers that are not part of adhesive structures in intact cells
EP4153226A1 (en) Antibody that binds specifically to the sars cov 2 spike protein, and methods for its manufacture
BR112018069332A2 (pt) composição e combinação farmacêutica para tratamento e/ou prevenção do câncer, anticorpo ou fragmento do mesmo e método para tratar e/ou prevenir um câncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.